Edition:
India

Anixa Biosciences Inc (ANIX.OQ)

ANIX.OQ on NASDAQ Stock Exchange Capital Market

2.39USD
12:08am IST
Change (% chg)

$0.00 (+0.00%)
Prev Close
$2.39
Open
$2.36
Day's High
$2.48
Day's Low
$2.36
Volume
28,526
Avg. Vol
70,947
52-wk High
$4.15
52-wk Low
$1.33

Latest Key Developments (Source: Significant Developments)

Anixa Biosciences Says Breast Cancer Vaccine Technology Nearing FDA Submission
Tuesday, 28 Jul 2020 

July 28 (Reuters) - Anixa Biosciences Inc ::ANIXA BIOSCIENCES BREAST CANCER VACCINE TECHNOLOGY NEARING FDA SUBMISSION.ANIXA BIOSCIENCES INC - CO, CLEVELAND CLINIC INTEND TO FILE IND APPLICATION WITH FDA BY END OF CURRENT QUARTER.ANIXA BIOSCIENCES INC - CO'S PROPHYLACTIC BREAST CANCER VACCINE IS MAKING PROGRESS TOWARDS CLINICAL TRIALS.  Full Article

Anixa Biosciences Provides Update On CAR-T Program
Friday, 13 Dec 2019 

Dec 13 (Reuters) - Anixa Biosciences Inc ::ANIXA BIOSCIENCES PROVIDES UPDATE ON CAR-T PROGRAM.ANIXA BIOSCIENCES- EXPERIMENTAL RESULTS SHOW EFFICACY OF CAR-T TECHNOLOGY AS OVARIAN CANCER TREATMENT COULD BE IMPROVED BY MORE GENETIC ENGINEERING.ANIXA BIOSCIENCES - DECISION HAS BEEN MADE TO OPTIMIZE CAR-T THERAPY AND FILE AN IND APPLICATION WITH US. FDA IN FUTURE.ANIXA BIOSCIENCES - OPTIMIZATION WORK ON CAR-T PROGRAM MAY TAKE EXTRA YEAR, RESULTING IN FILING OF IND IN LATE 2020, CLINICAL TRIALS TO START 2021.  Full Article

Anixa Biosciences Announces Collaboration with Urology Centers of Alabama
Friday, 22 Nov 2019 

Nov 22 (Reuters) - Anixa Biosciences Inc ::ANIXA BIOSCIENCES - ANNOUNCED COLLABORATION WITH UROLOGY CENTERS OF ALABAMA (UCA) IN CCHEK EARLY PROSTATE CANCER DETECTION STUDY.  Full Article

Anixa Biosciences says Co, Certain Current & Former Officers Entered Settlement Agreement With Co's Stockholder
Wednesday, 28 Aug 2019 

Aug 27 (Reuters) - Anixa Biosciences Inc ::ANIXA BIOSCIENCES - ON AUG 21, CO, CERTAIN OF ITS CURRENT & FORMER OFFICERS ENTERED SETTLEMENT AGREEMENT WITH STOCKHOLDER OF COMPANY.ANIXA BIOSCIENCES - SETTLEMENT AGREEMENT RESOLVES LAWSUIT BROUGHT DERIVATIVELY ON BEHALF OF CO IN DELAWARE COURT OF CHANCERY.ANIXA BIOSCIENCES INC - ALL OF CLAIMS ASSERTED IN DERIVATIVE ACTION WILL BE DISMISSED.  Full Article

BRIEF-Anixa, Ontochem Announce Completion Of Initial Screening Program And Identification Of Additional Covid-19 Compounds

* ANIXA AND ONTOCHEM ANNOUNCE COMPLETION OF INITIAL SCREENING PROGRAM AND IDENTIFICATION OF ADDITIONAL COVID-19 COMPOUNDS Source text for Eikon: Further company coverage: